All In Biotech

Drug Trial Radar · NCT01611974

Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients

A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients

Last checked: Nov 19, 2026Latest source record: Jun 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

120

Actual

Start

Jul 17, 2012

Primary completion

Dec 5, 2014

Study completion Dec 5, 2014

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
First posted
Jun 5, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess safety, antiviral activity, and pharmacokinetics of different doses of maribavir administered orally for up to 24 weeks for treatment of CMV infections that are resistant or refractory to treatment with ganciclovir/valganciclovir or foscarnet in recipients of stem cell or solid organ transplants.

Conditions

  • Cytomegalovirus (CMV)

Interventions

  • MaribavirDrug

    Tablet for oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Confirmed Undetectable Plasma Cytomegalovirus (CMV) Within 6 WeeksTime frame: 6 weeks
  2. Number of Participants With a Treatment Emergent Adverse Event (TEAE).Time frame: 25 weeks

Locations

32 sites in 1 country. Site status is shown where the registry gives one.

  • UCLA Medical Center

    Los Angeles, California

  • Stanford University Medical Center

    Stanford, California

  • University of Colorado

    Denver, Colorado

  • Yale University

    New Haven, Connecticut

  • University of Florida

    Gainesville, Florida

  • Tampa General Hospital

    Tampa, Florida

  • Emory University

    Atlanta, Georgia

  • Northwestern University Medical Center

    Chicago, Illinois

  • University of Chicago

    Chicago, Illinois

  • Ochsner Clinic Foundation

    New Orleans, Louisiana

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • University of Massachusetts

    Worcester, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Henry Ford Health Care System

    Detroit, Michigan

  • University of Minnesota Medical Center

    Minneapolis, Minnesota

  • University of Nebraska

    Omaha, Nebraska

  • Columbia University

    New York, New York

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Wake Forest Medical Center

    Winston-Salem, North Carolina

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • Nationwide Children's Hospital

    Columbus, Ohio

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Albert Einstein Medical Center

    Philadelphia, Pennsylvania

  • University of Pittsburg

    Pittsburgh, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • Vanderbilt Medical Center

    Nashville, Tennessee

  • Methodist Healthcare System

    San Antonio, Texas

  • University of Utah

    Salt Lake City, Utah

  • University of Washington

    Seattle, Washington

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.